



REGULATORY DEVELOPMENTS

European Food Safety Authority launches public consultation on risk assessment of nanomaterials in food and feed

The European Food Safety Authority (EFSA) has launched a public consultation on its draft guidance document for engineered nanomaterial applications in food and feed.

The guidance document was prepared by the Scientific Committee in response to a request from the European Commission. It offers guidance for the risk assessment of applications involving the use of nanoscience and nanotechnology in the area of food and feed, including food additives, enzymes, flavorings, food contact materials, novel foods, feed additives and pesticides.

Comments on the draft guidance can be submitted until 25 February 2011. In addition to the public consultation, EFSA will meet with EU Member State representatives to discuss the document.

<http://www.efsa.europa.eu/en/consultations/call/scaf110114.htm>

German federal government announced its “Nanotechnology Action Plan 2015” on 13 January 2011

The aim of the “Nanotechnology Action Plan 2015” announced by German federal government is to derive maximum benefit from nanotechnology and further solidify the country’s position in the innovative field.

The government plan involves strengthened funding for nanotechnology, improved conditions for starting a business, and a reduction in bureaucracy, as well as faster implementation of research results and better framework conditions.

<http://www.proactiveinvestors.com.au/companies/news/13096/nanostart-to-benefit-from-germanys-nanotechnology-action-plan-for-2015-13096.html>

This newsletter is provided as a public service and resource to the nanomedicines scientific and regulatory community. The mention of any organizations, conferences or other events in this newsletter IS FOR INFORMATIONAL PURPOSES ONLY and does not represent an endorsement by the Nanomedicines Alliance or any of its members.

CONFERENCES AND WORKSHOPS

Proceed with caution? - Concept and Application of the Precautionary principle in Nanobiotechnology

February 20 - 25, 2011; Muenster Germany

- Risk assessment in nanobiotechnology: concepts, methods, practical experience
- Ethical aspects of nanobiotechnology: personalized medicine, human enhancement, fair access, data protection, privacy
- Precautionary principle in legal and political documents at the European level
- Theoretical conceptions of the precautionary principle in the philosophical debate
- Legal aspects of the precautionary principle
- Implementation of the precautionary principle in nanobiotechnology

http://www.nanoforum.org/dateien/temp/call_for_papers_pp_in_nanobio.pdf?26112010035011

Advanced Technologies for an Ageing Population – sponsored by Institute of Nanotechnology

March 23 – 24, 2011; Glasgow UK

- How nanotechnology can help provide both improved treatments for conditions associated with ageing, and to contribute to a reduction in the overall costs of healthcare;
- In particular, new approaches to diagnosing and treating degenerative diseases associated ageing;
- New assistive technologies;
- Demographic trends;
- Ethical issues and challenges.

<http://www.nano.org.uk/conferences/ageing2011/overview.htm>

2011 AAPS Drug Delivery Workshop

April 14 – 15, 2011; Baltimore MD

- Emerging oral delivery strategies and technologies to enable biopharmaceutical performance of BCS II, III and IV molecules
- Physicochemical and biopharmaceutical properties and evaluation tools
- Lipid-based systems and solid dispersions
- Prodrugs and nanoparticles

<http://www.aaps.org/meetings/workshops/OralDelivery/index.asp>

International Conference on Biotechnology and Nanotechnology

April 27-29, 2011; Venice Italy

For academic scientists, leading engineers, industry researchers and scholar students to exchange experience and share research results of:

- All aspects of biotechnology and nanotechnology
- Practical challenges and solutions

<http://www.waset.org/conferences/2011/rome/icbn/index.php>

2011 National Biotechnology Conference – sponsored by AAPS

May 16 – 18, 2011; San Francisco CA

Symposium on Targeted Nanotheragnostics: Scientific Achievements and Commercialization Challenges, May 16, 2011: 1:30 – 4:00 pm.

- Promising advances in scientific strategies and approaches that combine disease diagnosis with therapy (Nanotheragnostics);
- Nanodevices;
- Safety concerns on the interaction of nanomaterials and nanoparticles with the human body;
- Pharmacokinetics and biodistribution of nanoparticles;
- Formulation, processing and manufacturing of nanoparticles;
- Opportunities for future growth and commercialization of nanomedicinal products

http://www.nxtbook.com/nxtbooks/aaps/nbc2011_preprogram/#

Pharmaceutical Nanotechnology: Applications & Commercialization

June 29-30, 2011; London UK

- Engineering, formulation and drug delivery
- Nano-enabled nucleic acid therapeutic delivery
- Translating discoveries into commercial successes
- Regulatory considerations, IP issues and partnering opportunities

<http://smi-online.co.uk/events/overview.asp?is=4&ref=3484>

NanoFormulation2011

June 26 – July 1, 2011 ; Singapore

- Formulation of Nano-Biomaterials
- Handling and processing of Nanopowders
- Processing and Stabilization of Nanoparticle Suspensions
- Smart and Functional Materials in Formulations: Coating, Films and Tapes
- Safety and Health Effects and Nanoscale Materials – Towards Sustainable and Safety

<http://www.nanoformulation2011.com/>

NanoMedicine – 2011

November 3 – 5, 2011: Shenzhen, China

- Breaking Research of Nanomedicines
- Versatile Nanotech and Nanomaterials in Biomedicine
- Nanodevices and Diagnostic
- Nanomedicine Targeting Major Diseases
- Regenerative Nanomedicine
- Culturing Public Environment for Healthy Growth

<http://www.bitconferences.com/NanoMedicine2011/>

REFERENCE SECTION

Nanomedicine products on the market:

- http://www.nature.com/nbt/journal/v24/n10/fig_tab/nbt1006-1211_T2.html
- <http://www.nanotechproject.org/inventories/medicine/apps/>

CONTACT

For further information, or if you have any questions about the Nanomedicines Alliance, please contact the Nanomedicines Alliance Secretariat at 1-202-230-5607.